Michael Mondada
About Michael Mondada
Michael Mondada is a Senior Cell Therapy Account Specialist with a Bachelor of Business Administration in Marketing from Boise State University. He has extensive experience in the pharmaceutical industry, particularly in launching new products and therapies.
Work at Kite Pharma
Michael Mondada has been employed at Kite Pharma as a Senior Cell Therapy Account Specialist since 2019. In this role, he focuses on the sales and marketing of advanced cell therapies, particularly in the area of Car-T therapy. He coordinates with Authorized Treatment Centers to ensure effective follow-up for patients undergoing this innovative treatment. His work contributes to the broader mission of Kite Pharma in delivering transformative therapies to patients.
Previous Experience in Oncology Sales
Before joining Kite Pharma, Michael Mondada worked at Gilead Sciences as an Oncology Therapeutic Specialist from 2014 to 2019. His responsibilities included community education and patient identification for Yescarta Car-T therapy. Prior to Gilead, he served as an Oncology Senior Sales Professional at SANOFI-AVENTIS from 2008 to 2011, where he gained extensive experience in oncology sales. He also held the position of Territory Medical Device Manager at SANOFI-AVENTIS from 2012 to 2014.
Education and Expertise
Michael Mondada studied at Boise State University, where he earned a Bachelor of Business Administration with a focus on Marketing. His educational background provides a solid foundation for his expertise in launching new geographies for pharmaceutical products. This combination of education and practical experience positions him effectively within the pharmaceutical industry.
Specialization in Cell Therapy
Michael Mondada specializes in cell therapy, particularly in the context of oncology. His role at Kite Pharma involves not only sales but also the marketing of targeted therapies such as Zydelig, which is used for chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL). His focus on innovative therapies reflects the evolving landscape of cancer treatment.